These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 23154454)

  • 1. Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?
    Caraux A; Vincent L; Bouhya S; Quittet P; Moreaux J; Requirand G; Veyrune JL; Olivier G; Cartron G; Rossi JF; Klein B
    Oncotarget; 2012 Nov; 3(11):1335-47. PubMed ID: 23154454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation.
    Takamatsu H; Takezako N; Zheng J; Moorhead M; Carlton VEH; Kong KA; Murata R; Ito S; Miyamoto T; Yokoyama K; Matsue K; Sato T; Kurokawa T; Yagi H; Terasaki Y; Ohata K; Matsumoto M; Yoshida T; Faham M; Nakao S
    Ann Oncol; 2017 Oct; 28(10):2503-2510. PubMed ID: 28945825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?
    Kazandjian D; Mo CC; Landgren O; Richardson PG
    Br J Haematol; 2020 Dec; 191(5):692-703. PubMed ID: 32501533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies-back to the future!
    Kazandjian D; Dew A; Hill E
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101150. PubMed ID: 32139015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial.
    Mai EK; Benner A; Bertsch U; Brossart P; Hänel A; Kunzmann V; Naumann R; Neben K; Egerer G; Ho AD; Hillengass J; Raab MS; Neubauer A; Peyn A; Ko YD; Peter N; Scheid C; Goldschmidt H
    Br J Haematol; 2016 Jun; 173(5):731-41. PubMed ID: 26990892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy.
    Voorhees PM; Usmani SZ
    Clin Adv Hematol Oncol; 2016 Sep; 14(9):719-28. PubMed ID: 27673290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of autologous stem-cell transplantation in multiple myeloma in 2021.
    Mina R; Gay F
    Curr Opin Oncol; 2021 Nov; 33(6):642-647. PubMed ID: 34419954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [High dose melphalan (HDM) is superior to cyclophosphamide plus etoposide and busulfan (CVB) as the conditioning regimen in autologous stem cell transplantation for multiple myeloma].
    Gu JL; Li J; Liu JR; Zou WY; Huang BH; Zheng D; Wang HH
    Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):732-737. PubMed ID: 31648473
    [No Abstract]   [Full Text] [Related]  

  • 9. High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation.
    Nath CE; Trotman J; Tiley C; Presgrave P; Joshua D; Kerridge I; Kwan YL; Gurney H; McLachlan AJ; Earl JW; Nivison-Smith I; Zeng L; Shaw PJ
    Br J Clin Pharmacol; 2016 Jul; 82(1):149-59. PubMed ID: 26879446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delaying the use of high-dose melphalan with stem cell rescue in multiple myeloma is ready for prime time.
    Kazandjian D; Landgren O
    Clin Adv Hematol Oncol; 2019 Oct; 17(10):559-568. PubMed ID: 31730582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma.
    Rossi G; Falcone AP; Minervini MM; De Cillis GP; De Waure C; Sisti LG; Giambra V; Valente D; Chiello V; Scalzulli PR; Carella AM; Cascavilla N
    Cytometry B Clin Cytom; 2019 May; 96(3):195-200. PubMed ID: 30549231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Veeraputhiran M; Jain T; Deol A; Ayash L; Kim S; Dyson G; Bhutani D; Lum LG; Ratanatharathorn V; Uberti JP; Abidi MH
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation.
    Fleming S; Harrison SJ; Blombery P; Joyce T; Stokes K; Seymour JF; Prince HM; Ritchie D
    Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):291-6. PubMed ID: 24629850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phagocyte function decreases after high-dose treatment with melphalan and autologous stem cell transplantation in patients with multiple myeloma.
    Wichert S; Pettersson Å; Hellmark T; Johansson Å; Hansson M
    Exp Hematol; 2016 May; 44(5):342-351.e5. PubMed ID: 26774385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased plasma-immune cytokines throughout the high-dose melphalan-induced lymphodepletion in patients with multiple myeloma: a window for adoptive immunotherapy.
    Condomines M; Veyrune JL; Larroque M; Quittet P; Latry P; Lugagne C; Hertogh C; Kanouni T; Rossi JF; Klein B
    J Immunol; 2010 Jan; 184(2):1079-84. PubMed ID: 19966210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.
    Gimsing P; Hjertner Ø; Abildgaard N; Andersen NF; Dahl TG; Gregersen H; Klausen TW; Mellqvist UH; Linder O; Lindås R; Tøffner Clausen N; Lenhoff S
    Bone Marrow Transplant; 2015 Oct; 50(10):1306-11. PubMed ID: 26121108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment.
    Liu J; Yan W; Fan H; Xu J; Li L; Du C; Mao X; Yan Y; Xu Y; Sui W; Deng S; Yi S; Anderson KC; Qiu L; Zou D; An G
    Cancer Res Commun; 2023 Sep; 3(9):1770-1780. PubMed ID: 37680953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.
    Mark TM; Guarneri D; Forsberg P; Rossi A; Pearse R; Perry A; Pekle K; Tegnestam L; Greenberg J; Shore T; Gergis U; Mayer S; Van Besien K; Ely S; Jayabalan D; Sherbenou D; Coleman M; Niesvizky R
    Biol Blood Marrow Transplant; 2017 Jun; 23(6):930-937. PubMed ID: 28285081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
    Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
    J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).
    Roussel M; Moreau P; Huynh A; Mary JY; Danho C; Caillot D; Hulin C; Fruchart C; Marit G; Pégourié B; Lenain P; Araujo C; Kolb B; Randriamalala E; Royer B; Stoppa AM; Dib M; Dorvaux V; Garderet L; Mathiot C; Avet-Loiseau H; Harousseau JL; Attal M;
    Blood; 2010 Jan; 115(1):32-7. PubMed ID: 19884643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.